Koers Amarin Corporation plc (ADR) Xetra
Aandelen
EH3A
US0231112063
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
||
0,675 EUR | 0,00% |
|
Omzet 2024 * | 202 mln. 189 mln. | Omzet 2025 * | 215 mln. 201 mln. | Marktkapitalisatie | 288 mln. 269 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -70 mln. -65,36 mln. | Nettowinst (verlies) 2025 * | -64 mln. -59,76 mln. | EV/omzet 2024 * | 1,21 x |
Nettoliquiditeiten 2024 * | 43,92 mln. 41,01 mln. | Nettoliquiditeiten 2025 * | 159 mln. 148 mln. | EV/omzet 2025 * | 0,6 x |
K/w-verhouding 2024 * |
-3,98
x | K/w-verhouding 2025 * |
-4,21
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,48% |
Recentste transcriptie over Amarin Corporation plc (ADR)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Aaron Berg
CEO | Chief Executive Officer | 61 | 01-11-12 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 20-06-22 |
Compliance Officer | 55 | 15/11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 28-02-23 |
Odysseas Kostas
CHM | Chairman | 49 | 28-02-23 |
Keith Horn
BRD | Director/Board Member | 66 | 28-02-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,13% | 122 mld. | |
+19,65% | 113 mld. | |
+18,92% | 26,49 mld. | |
-23,84% | 19,4 mld. | |
-18,17% | 16,24 mld. | |
-45,95% | 15,15 mld. | |
-19,28% | 15,4 mld. | |
+63,81% | 14,93 mld. | |
+1,94% | 13,52 mld. |
- Beurs
- Aandelen
- Koers AMRN
- Koers EH3A